Subscribe to our Newsletters !!
How are viruses different from bacteria apex ? O
Pharmaceutical laboratories have been adopting imm
Generally, a debate about Isopure protein and regu
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Approximately 90 percent of Sinovac Biotech Ltd employees and their families have obtained an experimental coronavirus vaccine developed by the Chinese company under the nation’s emergency usage programme, its chief executive said on Sunday.
The extent of inoculations under the emergency programme, which China launched in July but has released few details about, points to how actively it is using experimental vaccines in the hopes of protecting essential workers against a potential COVID-19 resurgence, even as trials are still underway.
The programme is meant for certain groups, including medical staffers and people who work in food markets and in the transport and service sectors.
Sinovac, whose CoronaVac is currently in Phase 3 clinical trials and has been included in the emergency scheme, offered the candidate vaccine to about 2,000 to 3,000 employees and their families on a voluntary basis, CEO Yin Weidong told Reuters.
“As a vaccine developer and manufacturer, a new outbreak could directly affect our vaccine production,” Yin said on the sidelines of an international trade fair in Beijing, explaining why his company was included in the emergency programme.
Data gathered from the programme could provide evidence of the vaccine’s safety, but such data, which is not part of the registered clinical trial protocols, won’t be used as main materials that regulators review in judging whether to approve the vaccine for industrial use, Yin said.
He said those who chose to be inoculated, including his wife and parents, had been informed of the possible side effects prior to taking the shot, and that its vaccine finishing only premature and mid-stage trials.
Yin, who took the shot, said doctors asked about their health conditions prior to the vaccination, and the incidence rate of adverse reaction among those vaccinated has been”quite low”.
Side effects after taking CoronaVac include fever, fatigue and pain, with mostly moderate symptoms, according to results of a mid-stage trials supervised by Sinovac, involving 600 participants and published last month ahead of peer review.
No vaccine has passed final, large-scale trials to prove it is effective and safe enough to protect people against the virus which has led to over 870,000 deaths globally.
